Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of 0.125% vs 0.25% Bupivacaine QLB in Pediatric LPEC
NCT04998071Unknown
- Sponsor
- Queen Sirikit National Institute of Child Health
- Start
- Aug 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of bupivacaine in postoperative pain, sponsored by Queen Sirikit National Institute of Child Health. Primary endpoint: Quality of postoperative analgesia at 24 hours. Status: unknown.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04998071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04998071.